Headline

Novavax is uniquely qualified to address the enduring need for innovative vaccines

Mr. Erck was named president and chief executive officer of Novavax in April 2011. He became a Novavax director in June 2009 and served as its executive chairman of the board beginning in February 2010. From 2000 to 2008, Mr. Erck was president and chief executive officer of IOMAI Corporation, leading the company through an initial public offering and a merger with Intercell, an Austrian vaccine company, and through the development of a late-stage infectious disease product candidate. Mr. Erck previously served as president and chief executive officer at Procept, a publicly traded immunology company, as vice president of corporate development at Integrated Genetics (now Genzyme), and in management positions within Baxter International. Mr. Erck currently sits on the board of directors of MaxCyte, Inc. He received an undergraduate degree from the University of Illinois and a master’s degree in business administration from the University of Chicago Booth School of Business.

Dr. Glenn is the president of research and development and leads the discovery, clinical, and regulatory teams. He has spent 28 years in the design and development of vaccines, vaccine delivery, and adjuvants. He has led the development of products from concept to late-stage clinical development, including COVID-19, RSV, recombinant adjuvanted seasonal and pandemic influenza vaccines, Ebola, and an Enterotoxigenic E. coli vaccine patch, and participated in other programs including the development of a malaria vaccine. He is the cofounder of IOMAI and provided the scientific and technical leadership that led to the acquisition by Intercell in 2008. He worked for Intercell from 2008 to 2010. He is the coauthor of more than 100 peer-reviewed scientific publications. Dr. Glenn was board certified and practiced pediatrics prior to completing a Medical Research Fellowship at the Walter Reed Army Institute of Research where he continued as a clinician-researcher prior to entering into commercial vaccine development in 1997. Dr. Glenn received a bachelor of arts degree in biology and chemistry from Whitman College in Washington and a doctor of medicine degree from Oral Roberts University School of Medicine in Oklahoma.

Mr. Covino joined Novavax in November 2020 as executive vice president and chief financial officer with responsibility for financial strategy, performance and reporting and corporate funding. Prior to joining Novavax, Mr. Covino was group chief financial officer at GlaxoSmithKline’s TESARO Oncology Division, where he also served as senior vice president and chief accounting officer. He previously served as chief accounting officer at Biogen Inc. as well as vice president, corporate internal audit and control and vice president, international finance for Boston Scientific. Earlier in his career, Mr. Covino spent 10 years at international accounting and consulting firm PricewaterhouseCoopers. He holds a Bachelor of Science in Business Administration from Bryant University.

Mr. Crowley is chief operations officer with responsibility for all operations, including Quality, Manufacturing, Supply Chain and Regulatory Affairs. He joined Novavax in December 2020, bringing more than two decades of experience in biopharmaceutical operations and executive management. Prior to joining Novavax, Mr. Crowley was executive vice president, technical operations at TerSera Therapeutics, where he held responsibility for technical support, development and strategy for the company’s products, created the initial quality systems and managed all technical CMC activities., Mr. Crowley served as senior vice president, operations and quality assurance for Crealta Pharmaceuticals 2014-2016, where he was responsible for supply chain, quality systems and the global regulatory affairs. Earlier, Mr. Crowley held the role of co-president and chief operating officer at Savient Pharmaceuticals. Mr. Crowley holds a bachelor of science degree in chemistry from Denison University and a master of science degree in chemical engineering from the University of Pennsylvania.

Dr. Dubovsky is executive vice president, chief medical officer with responsibility for medical and clinical affairs and related activities at Novavax. A recognized leader in vaccine development, Dr. Dubovsky brings more than 20 years of infectious disease experience to Novavax. He joined Novavax from AstraZeneca, where he was head of clinical engagement and policy and deputy chief medical officer for clinical affairs. Before that, he oversaw the clinical development of early and late-stage infectious disease and vaccine assets at MedImmune, which was subsequently acquired by AstraZeneca. Previously, he created and managed a portfolio of 25 malaria vaccine candidates spanning early candidate optimization to Phase 3 clinical studies at PATH’s Malaria Vaccine Initiative. He is the coauthor of more than 50 peer-reviewed scientific publications and currently sits on the board of directors of the Sabin Institute. Dr. Dubovsky earned his master of public health degree from Johns Hopkins University and his doctor of medicine degree from the University of Alabama. He completed his pediatric training at Stanford University, his pediatric infectious disease fellowship at the Center for Vaccine Development at the University of Maryland, and his preventive medicine training at Johns Hopkins University.

Mr. Herrmann joined Novavax in 2010 and is responsible for managing all of its legal affairs, including its patent portfolio, transactional and contractual matters, and public securities filings, and oversight of corporate and business development activities, along with attending to all the duties of corporate secretary. Mr. Herrmann also works with the senior management team at Novavax to define and develop corporate policies and procedures. Prior to joining Novavax, Mr. Herrmann was general counsel at Ore Pharmaceuticals and deputy general counsel at Gene Logic before it became Ore Pharmaceuticals. Mr. Herrmann previously worked as senior counsel for Celera Genomics and as senior corporate counsel at Baxter Healthcare in its renal division. Mr. Herrmann received a bachelor of arts degree in political science and history from Brown University and a juris doctorate from the University of Illinois.

Ms. Hoyt is executive vice president of human resources with full responsibility for the company’s human resources duties and activities including talent acquisition, retention and development as well as rewards and benefits. Her significant expertise and experiences were pivotal in the development and expansion of the company’s employee base in both the United States and Sweden. Ms. Hoyt has implemented leadership strategies for the development of comprehensive human resources programs in support of the company’s strategic plans, while also driving cultural development (a quality for which Novavax has been recognized several times, including placement on the Washington Post’s Top Workplaces). Prior to joining Novavax in 2008 as vice president of human resources, Ms. Hoyt held positions of increasing responsibility at several organizations, including ChoicePoint, 3e Technologies International, Inc., and TRW. Ms. Hoyt received a bachelor of science degree in business administration from Shepherd University and a master of science degree in human resource management from Marymount University.

Mr. Machielse brings more than 25 years of biotechnology industry experience to Novavax. He was most recently chief executive officer of rare disease company Vtesse, before its acquisition by Sucampo Pharmaceuticals, Inc., now a part of Mallinckrodt. Previously, he was chief operating officer at Omthera Pharmaceuticals, where he oversaw development and approval of a treatment for hypertriglyceridemia and was integral to the company’s IPO and acquisition by AstraZeneca. Earlier, as executive vice president of operations for MedImmune, later acquired by AstraZeneca, he led worldwide development and operations of the company’s therapeutic antibodies, small molecules and vaccine products. Additionally, he was responsible for development of MedImmune’s H1N1 influenza vaccine, which was the first to be approved by FDA. He currently sits on the board of directors of Comet Therapeutics, Complexa Therapeutics and Polyneuron. Mr. Machielse received a bachelor of science degree in medical biology and a master of science degree in biochemistry from the University of Utrecht in the Netherlands.

Mr. Trizzino is executive vice president, chief business officer and chief commercial officer with responsibility for global commercial strategy and execution and oversight of IT, investor and public relations, and corporate affairs. He has broad experience in publicly held companies and in vaccines, with previous roles overseeing commercialization, policy, strategy, business development, financing, and investor and public relations. Since rejoining Novavax in 2014, he has held roles of increasing responsibility, including chief financial officer and senior vice president of commercial operations. Mr. Trizzino served as CEO of Immunovaccine in 2011, successfully leading the company into clinical development while securing the funding commitments required to advance the company’s lead candidate. Earlier in his career, Mr. Trizzino held leadership roles at several companies with a focus in infectious disease vaccine markets, including MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.

Mr. Wilson is executive vice president and NanoFlu general manager with responsibility for leading the efforts to advance NanoFlu through global licensure. Mr. Wilson joined Novavax in 2011 as senior vice president, business development, and most recently was responsible for global business development, quality, and program management functions across the company’s entire pipeline. Prior to joining Novavax in November 2011, Mr. Wilson was most recently the chief financial officer at Supernus Pharmaceuticals. He was previously senior vice president, chief financial officer, and general counsel of Iomai Corporation, which was acquired in 2008 by Intercell AG, during which time he successfully negotiated a $128 million government contract with the Office of Biomedical Research and Development Authority (BARDA) at the US Department of Health and Human Services. Mr. Wilson was also the acting general counsel of North American Vaccine, Inc. until its acquisition by Baxter International in 2000. Mr. Wilson received a bachelor of arts degree in history from Princeton University and a master degree in business administration and a juris doctorate from the University of Virginia.

Mr. Andréasson is senior vice president of corporate development with responsibility for identifying, prioritizing, and evaluating new strategic opportunities for Novavax that leverage core strengths and accelerate growth initiatives. Mr. Andréasson joined Novavax in June 2014 with many years of experience in biopharmaceutical operations, executive management, and strategic development. From 2012 to 2013, he served as the chief executive officer of Isconova AB in Uppsala, Sweden, a leading international vaccine adjuvant company acquired by Novavax in 2013 and currently operating as Novavax AB. Prior to his role at Isconova AB, Mr. Andréasson served as the chief executive officer of Beta-Cell NV in Brussels, Belgium from 2008 to 2012 and as chief executive officer of Active Biotech AB in Lund, Sweden from 1999 to 2008. Mr. Andréasson spent a number of years in roles inside Pharmacia Corporation, including president of Pharmacia SA, France, president of KabiPharmacia International, and president of Pharmacia Arzneimittel GmbH, Germany. Mr. Andréasson received a bachelor of science degree in business administration and economics from the Stockholm School of Economics in Sweden.

Mr. Czworka is senior vice president of sales with responsibility for global customer engagement activities. He brings more than two decades of biopharmaceutical experience to Novavax, most recently serving as vice president, global customer engagement at U.S. Pharmacopeia. In sales and marketing leadership positions at Osiris Therapeutics, Auxilium Pharmaceuticals, MedImmune and TAP Pharmaceuticals, Mr. Czworka has assembled, developed, deployed and directed award-winning global sales and marketing teams to achieve business objectives. He has launched multiple medications across a variety of therapeutic areas while increasing patient access to vital treatments. Mr. Czworka received a bachelor of science degree in business administration – marketing from the University of Central Florida.

Dr. Hahn is senior vice president of CMC for NanoFlu with responsibility for leading all CMC activities for the NanoFlu program. Dr. Hahn has 28 years of commercial vaccine and antibody manufacturing experience and a proven track record with clinical and commercial products, process innovation, technology transfer, facility start-up, GMP compliance, and regulatory inspections. Dr. Hahn joined Novavax in June 2011 as senior vice president of manufacturing and process development and was later named senior vice president of global manufacturing operations with responsibility for production sites in the United States and Europe. Prior to joining Novavax, he was vice president of antibody manufacturing and later vice president of vaccine manufacturing at MedImmune, LLC, with responsibilities for sites in the United States and Europe. Prior to MedImmune, he spent more than 15 years in vaccine manufacturing with Merck & Co. Dr. Hahn received a bachelor of science degree in chemical engineering from Lehigh University and a master of science and a doctorate degree in chemical engineering from Stanford University.

Mr. Lee is senior vice president and chief information officer with responsibility for leading the information technology operations, network infrastructure, enterprise applications, project management, and cybersecurity programs. He works closely with senior management to align IT investments with corporate strategy and business objectives. He joined Novavax in 2017 as senior director of IT with more than 20 years of IT experience, the vast majority of which has been in the life sciences industry. Prior to joining Novavax, he served as vice president of cloud solutions at IPDS, Inc., an information technology services company, where he led development and implementation of the cloud solutions portfolio. Mr. Lee previously held positions of increasing responsibility at Human Genome Sciences (HGS) leading up to its acquisition by GlaxoSmithKline (GSK). He led the global IT integration and successfully completed the disposition of all IT assets during the transition of HGS into GSK.

Mr. Rosen is senior vice president of commercial strategy with responsibility for leading commercial strategy efforts instrumental to ensuring future patient access to Novavax vaccines. Mr. Rosen joined Novavax in 2015 as vice president of market access and policy and was named vice president of commercial strategy in June 2018. He came to Novavax with more than 20 years of industry, legal, and patient advocacy experience with the vast majority engaged in government affairs, advocacy, reimbursement, and policy work. Prior to Novavax, Mr. Rosen was most recently the chief policy, advocacy and patient access officer for the Leukemia & Lymphoma Society, where he oversaw all legislative and regulatory efforts and the delivery of patient services nationwide; prior to that, he developed and ran the government affairs, policy, and alliance development functions for MedImmune. Mr. Rosen currently serves as chair of the board of directors of Learning Undefeated, a nonprofit that provides STEM education and workforce development to underserved communities. Mr. Rosen received a bachelor of arts degree in history and psychology from Tufts University and a juris doctorate from Hofstra University School of Law.

Ms. Taylor is senior vice president, investor relations and corporate affairs with responsibility for investor relations, public relations, and corporate communications activities at Novavax. She brings more than 25 years of communications and commercial leadership to Novavax. Most recently, she was vice president of global corporate affairs and communications at Autolus Therapeutics plc, where she led all financial, scientific, and corporate communications. Prior to Autolus, Ms. Taylor was senior vice president of global investor relations and corporate affairs at Sucampo. Earlier in her career, she held positions of increasing responsibility at MedImmune LLC, the global biologics arm of AstraZeneca, including head of marketing responsible for the commercialization of the company’s respiratory syncytial virus and influenza franchises, as well as roles at Pfizer, where she served in key brand and consumer marketing roles. She has also worked in public relations and communications roles in agency and nonprofit settings. Ms. Taylor earned a master of business administration degree from Columbia University and a bachelor of arts degree in foreign affairs from University of Virginia.

Dr. Ukwu is senior vice president, and chief regulatory and quality officer with responsibility for leading global regulatory strategy and execution as well as the quality assurance function. Dr. Ukwu joined Novavax in January 2021, bringing more than two decades of experience in regulatory affairs and quality and successfully bringing numerous products through regulatory approval. Prior to joining Novavax, Dr. Ukwu was chief regulatory officer and global head of quality and regulatory at Otsuka Pharmaceuticals, where she led the regulatory and quality organizations with a focus on compliance excellence, inspection readiness and engagement with health authorities and regulatory agencies. She previously held senior leadership roles at PPD as senior vice president and head of Global Regulatory Affairs where she had responsibilities for regulatory services across all PPD lines of business; Wyeth Pharmaceuticals, Inc.(Pfizer), where she was vice president, regulatory affairs with responsibility that spanned vaccines, biologics, and pharmaceuticals and across all regions, and at Merck & Co., Inc., as head of vaccine regulatory development, vice president of global regulatory affairs and global regulatory policy. Dr. Ukwu holds medical and surgical degrees from the University of Jos School of Medicine in Nigeria, and completed internal medicine residency at University of Tennessee, Baptist Hospital and infectious diseases fellowship at Vanderbilt University Medical Center.

Mr. Webb is senior vice president of manufacturing with responsibility for overseeing antigen manufacturing and supply activities in support of Novavax’ vaccine candidates. Mr. Webb joined Novavax in May 2014 as senior director of manufacturing, named executive director of manufacturing in December 2016, and then named vice president of manufacturing in December 2018. Prior to joining Novavax, Mr. Webb held numerous operational leadership roles at GlaxoSmithKline and Human Genome Sciences where he had the opportunity to take multiple products from early clinical stage through licensure and launch. He received a bachelor of science degree in biology from Salisbury University and a master of science degree in biotechnology from Johns Hopkins University.